The once and future role of cytoreductive nephrectomy

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 4, 2008, Pages 346-352

  Neill, Mischel G ^a   Jewett, Michael A S ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Cytoreductive nephrectomy; Interfon; Interleukin 2; Metastatectomy; Renal cell carcinoma; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; INTERFERON; INTERLEUKIN 2; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ANGIOGENESIS; ANTIBODY SPECIFICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; METASTASIS; MOLECULAR DYNAMICS; MULTICENTER STUDY; NEPHRECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; LAPAROSCOPY; NEPHRECTOMY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 45949089028     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.05.029     Document Type: Review

References (32)

1. Janzen N.K., Kim H.L., Figlin R.A., et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin N Am 30 (2003) 843-852
2. Medical Research Council Collaborators. Interferon-α and survival in metastatic renal cell carcinoma: Early results of a randomized controlled trial. Lancet 353 (1999) 14-17
3. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib vs. interferon α in metastatic renal cell carcinoma. N Engl J Med 356 (2007) 115-124
4. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med 356 (2007) 125-134
5. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2. Cancer 80 (1997) 1198-1220
6. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously-treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
7. Zisman A., Pantuck A.J., Wieder J., et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20 (2002) 4559-4566
8. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon-α 2b compared with interferon-α 2b alone for metastatic renal cell carcinoma. N Engl J Med 345 (2001) 1655-1659
9. Mickisch G.H., Garin A., Van Poppel H., et al. Radical nephrectomy plus interferon-α based immunotherapy compared with interferon-α alone in metastatic renal cell carcinoma: A randomized trial. Lancet 358 (2001) 966-970
10. Bromwich E., Hendry D., and Aitchison M. Cytoreductive nephrectomy: Is it a realistic option in patients with renal cancer?. BJU Int 89 (2002) 523-525
11. Flanigan R.C., Mickisch G., Sylvester R., et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol 171 (2004) 1071-1076
12. Mosharafa A., Koch M., Shalhav A., et al. Nephrectomy for metastatic renal cell carcinoma: Indiana University experience. Urology 62 (2003) 636-640
13. Walther M.M., Patel B., Choyke P.L., et al. Hypercalcemia in patients with metastatic renal cell carcinoma: Effect of nephrectomy and metabolic evaluation. J Urol 159 (1997) 733-739
14. Fujikawa K., Matsui Y., Miura K., et al. Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy. J Urol 164 (2000) 673-675
15. Dadian G., Riches P.G., Henderson D.C., et al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol 74 (1994) 15-22
16. Lokich J. Spontaneous regression of metastatic renal cancer: Case report and literature review. Am J Clin Oncol 20 (1997) 416-418
17. Montie J.E., Stewart B.H., and Straffon R.A. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 117 (1977) 272-275
18. Rackley R., Novick A., Klein E., et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 152 (1994) 1399-1403
19. Krishnamurthi V., Novick A.C., and Bukowski R.M. Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 51 (1998) 933-937
20. Wagner J.R., Walther M.M., Linehan W.M., et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 162 (1999) 43-45
21. Bex A., Kerst M., Mallo H., et al. Interferon-α 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: A consecutive study. Eur Urol 49 (2006) 76-81
22. Halbert R.J., Figlin R.A., Atkins M.B., et al. Treatment of patients with metastatic renal cell carcinoma: A RAND Appropriateness Panel. Cancer 107 (2006) 2375-2383
23. Walther M.M., Lyne C., Libutti S.K., et al. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: A pilot study. Urology 53 (1999) 496-501
24. Rabets J.C., Kaouk J., Fergany A., et al. Laparoscopic vs. open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 64 (2004) 930-934
25. Matin S.F., Madsen L.T., and Wood C.G. Laparoscopic cytoreductive nephrectomy: The M. D. Anderson Cancer Center Experience. Urology 68 (2006) 528-532
26. Cohen H.T., and McGovern F.J. Renal cell carcinoma. N Engl J Med 353 (2005) 2477-2490
27. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with Bevacizumab. J Surg Oncol 91 (2005) 173-180
28. Bennett R.T., Lerner S.E., Taub H.C., et al. Cytoreductive surgery for Stage IV renal cell carcinoma. J Urol 154 (1995) 32-34
29. Franklin J.R., Figlin R., Rauch J., et al. Cytoreductive surgery in the management of metastatic renal cell carcinoma: The UCLA experience. Semin Urol Oncol 14 (1996) 230-236
30. Walther M.M., Yang J.C., Pass H.I., et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 158 (1997) 1675-1678
31. Fallick M.L., McDermott D.F., LaRock D., et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 158 (1997) 1691-1695
32. Wood C.G., Huber N., Madsen L., et al. Clinical variables that predict survival cytoreductive nephrectomy for metastatic renal cell carcinoma. J Urol 165 (2001) 184A